Orbital Radiation

Phase 2Small molecule

Orbital Radiation is one of 15 small molecule programs targeting B-cell Non Hodgkin Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell Non Hodgkin LymphomaActive, not recruiting

B-Cell Non Hodgkin LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in B-Cell Non Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

5 2

Adriamycin

Pfizer

Phase 2

1 3

Oncovin

Eli Lilly

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 5

Rayos

RRoxane Laboratories

Phase 2

4 6

Surovatamig

AstraZeneca

Phase 2

2 7

Polivy

Roche

Phase 1

1 8

COLUMVI

Roche

Phase 1

1 9

LUNSUMIO

Roche

Phase 1

1 10

Gazyva

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

B-Cell Non Hodgkin Lymphoma

NCT02494700

Clinical

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02494700·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orbital Radiation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orbital Radiation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orbital Radiation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Orbital Radiation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News